We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Sensitive PCR Test Detects Early Stage Lyme Disease

By LabMedica International staff writers
Posted on 19 Apr 2021
Print article
Image: Darkfield photomicrograph (magnified 400x) showing the presence of the spirochaete Borrelia burgdorferi, which is the pathogen that causes Lyme disease (Photo courtesy of [U.S.] Centers for Disease Control and Prevention via Wikimedia Commons)
Image: Darkfield photomicrograph (magnified 400x) showing the presence of the spirochaete Borrelia burgdorferi, which is the pathogen that causes Lyme disease (Photo courtesy of [U.S.] Centers for Disease Control and Prevention via Wikimedia Commons)
A highly sensitive blood test detects the bacteria that causes Lyme disease in early stages of the infection, when treatment can prevent the development of serious or fatal consequences of the chronic disease.

The successful treatment of Lyme disease (LD) is contingent on accurate diagnosis. However, current laboratory detection assays lack sensitivity in the early stages of the disease. Since delayed diagnosis of LD can result in high healthcare costs and great suffering to the patient, new highly sensitive tests are needed.

In this regard, investigators at the University of Leicester (United Kingdom) developed an internally controlled quantitative PCR test that targeted the multicopy terminase large subunit (terL) gene encoded by prophages that are only found in LD-causing bacteria. A prophage is a bacteriophage genome inserted and integrated into the circular bacterial DNA chromosome or present as an extrachromosomal plasmid. This is a latent form of a phage, in which the viral genes are present in the bacterium without causing disruption of the bacterial cell.

The newly developed Ter-qPCR test was based on the polymerase chain reaction (PCR), which amplifies small amounts of specific genetic material so that it can be detected. To increase the sensitivity of the test for detection of Borrelia burgdorferi, the causative agents of Lyme disease, the investigators adapted it to be specific for the prophage terL gene. The terL protein helps phages package their DNA.

The diagnostic potential of the Ter-qPCR test was evaluated using a set of blood and serum samples collected from healthy volunteers and individuals who were clinically diagnosed with Lyme disease. Results revealed that the detection limit of the Ter-qPCR test was estimated to be 22 copies, the equivalent of one bacterial cell in a bacteria spiked blood sample. Furthermore, significant quantitative differences were observed in terms of the amount of terL detected in healthy individuals and patients with either early or late Lyme disease.

"Early diagnosis of Lyme disease is absolutely vital in reducing suffering, because early Lyme can be treated, but late Lyme is very difficult to treat," said first author Dr. Jinyu Shan, a researcher in the department of respiratory sciences at the University of Leicester. "Current tests cannot typically detect the low numbers of bacteria in early-stage patient blood samples. Our goal was to design a highly sensitive test to help doctors to identify Lyme disease as early as possible. We are currently working with a commercial partner, and investigating regulatory issues and the potential for a clinical trial for this technology."

The Ter-qPCR test was described in the March 15, 2021, online edition of the journal Frontiers in Microbiology.

Related Links:
University of Leicester

New
Gold Supplier
SARS-CoV2 Antigen Rapid Test
SARS-CoV2 Antigen Rapid Test
New
Infant Heel Lancet
Unistik TinyTouch
New
D-Dimer ELISA Kit
D-Dimer AccuBind ELISA Kit
New
Silver Supplier
COVID-19 IgM & IgG Quality Control
COVID-19 IgM & IgG Quality Control

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.